91 related articles for article (PubMed ID: 23773757)
1. [Tert promoter mutations in melanoma: not only the MAP-kinase pathway].
Dereure O
Ann Dermatol Venereol; 2013; 140(6-7):487-8. PubMed ID: 23773757
[No Abstract] [Full Text] [Related]
2. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations in familial and sporadic melanoma.
Horn S; Figl A; Rachakonda PS; Fischer C; Sucker A; Gast A; Kadel S; Moll I; Nagore E; Hemminki K; Schadendorf D; Kumar R
Science; 2013 Feb; 339(6122):959-61. PubMed ID: 23348503
[TBL] [Abstract][Full Text] [Related]
4. Highly recurrent TERT promoter mutations in human melanoma.
Huang FW; Hodis E; Xu MJ; Kryukov GV; Chin L; Garraway LA
Science; 2013 Feb; 339(6122):957-9. PubMed ID: 23348506
[TBL] [Abstract][Full Text] [Related]
5. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
6. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.
Heidenreich B; Nagore E; Rachakonda PS; Garcia-Casado Z; Requena C; Traves V; Becker J; Soufir N; Hemminki K; Kumar R
Nat Commun; 2014 Feb; 5():3401. PubMed ID: 24569790
[TBL] [Abstract][Full Text] [Related]
7. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
[TBL] [Abstract][Full Text] [Related]
8. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway.
Maida Y; Kyo S; Kanaya T; Wang Z; Yatabe N; Tanaka M; Nakamura M; Ohmichi M; Gotoh N; Murakami S; Inoue M
Oncogene; 2002 Jun; 21(26):4071-9. PubMed ID: 12037663
[TBL] [Abstract][Full Text] [Related]
9. [MAP-Kinase pathway abnormalities in melanoma: B-RAF is not the sole cause].
Dereure O
Ann Dermatol Venereol; 2012 Oct; 139(10):691-2. PubMed ID: 23122387
[No Abstract] [Full Text] [Related]
10. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.
Dumaz N; Hayward R; Martin J; Ogilvie L; Hedley D; Curtin JA; Bastian BC; Springer C; Marais R
Cancer Res; 2006 Oct; 66(19):9483-91. PubMed ID: 17018604
[TBL] [Abstract][Full Text] [Related]
11. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
12. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
[TBL] [Abstract][Full Text] [Related]
13. Driver mutations in melanoma: lessons learned from bench-to-bedside studies.
Mehnert JM; Kluger HM
Curr Oncol Rep; 2012 Oct; 14(5):449-57. PubMed ID: 22723080
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
[TBL] [Abstract][Full Text] [Related]
15. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
16. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
17. Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma.
Hosono J; Nitta M; Masui K; Maruyama T; Komori T; Yokoo H; Saito T; Muragaki Y; Kawamata T
World Neurosurg; 2019 Jun; 126():624-630. PubMed ID: 30599247
[TBL] [Abstract][Full Text] [Related]
18. The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells.
Lefort K; Rouault JP; Tondereau L; Magaud JP; Doré JF
Oncogene; 2001 Nov; 20(50):7375-85. PubMed ID: 11704867
[TBL] [Abstract][Full Text] [Related]
19. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence.
Ohtani N; Zebedee Z; Huot TJ; Stinson JA; Sugimoto M; Ohashi Y; Sharrocks AD; Peters G; Hara E
Nature; 2001 Feb; 409(6823):1067-70. PubMed ID: 11234019
[TBL] [Abstract][Full Text] [Related]
20. The BRAF gene is frequently mutated in malignant melanoma.
Stratton MR; Wooster RW; Futreal PA
J Drugs Dermatol; 2004; 3(5):573-5. PubMed ID: 15552615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
